Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1b Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Seropositive Young Children

NCT04444284 is registered in ClinicalTrials.gov with Meissa Vaccines, Inc. as lead sponsor.

NCT NCT04444284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04444284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1b Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Seropositive Young Children
Lead sponsor
Meissa Vaccines, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 9, 2020
Completion date
May 7, 2021
Enrollment
34 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus infections